Large Venture Financings in November Point to Shift Among

Large Venture Financings in November Point to Shift Among Investors 
Concern Grows About Realizing Value Rather Than Exits, Burrill &
Company Says 
SAN FRANCISCO, CA -- (Marketwire) -- 12/03/12 --  At a time when life
sciences companies are feeling little leverage in M&A, partnering,
and IPO negotiations, a series of large venture rounds completed in
November suggests venture investors are willing to pony up additional
financing for promising companies in late-stage development to
realize the full value of their investments, according to Burrill &
Company. 
"Capital is expensive today, and life sciences companies too often
have little option when negotiating deals," says G. Steven Burrill,
CEO of Burrill & Company, a global financial services firm focused on
the life sciences. "The recent string of large, late-stage rounds
suggests a possible shift in posture among life sciences companies
and their investors as there is growing unwillingness to leave
substantial value on the table." 
Intarcia Therapeutics $210 million financing represented the largest
private financing of the month through a combination of existing and
new investors. It was among the largest amounts raised by a private
biotechnology company in the last 25 years. Intarcia raised $160
million in equity through a preferred stock private placement and $50
million in a private debt placement. Intarcia's ITCA 650 is a
once-yearly, injection-free treatment for type 2 diabetes that
provides subcutaneous delivery of the already-approved drug
exenatide. 
TauRx Pharmaceuticals, which had encouraging mid-stage trial results
for its experimental Alzheimer's drug, raised $112 million in
November. TauRx received $31.5 million as the first tranche of a
$111.8 million investment from Genting Management, a unit of the
Malaysian conglomerate Genting Berhad, in exchange for a 20 percent
stake in the biotech company. TauRx's experimental Alzheimer's drug
LMTX, works by keeping the tau proteins from clumping together, and
is the first such drug to be tested in a late-stage trial, according
to the company. 
And then there's Rib-X Pharmaceuticals, which closed an $18.7 million
first tranche of a $67.5 million preferred stock financing. A second
tranche is expected to close before the end of 2012. New investor
Vatera Healthcare Partners joined existing investors in the deal. The
money will be used to initiate a late-stage trial of Rib-X's
delafloxacin, a treatment for acute bacterial skin and skin structure
infections being developed as a first-line therapy for use in
hospitals prior to the availability of a specific diagnosis. Unlike
available first-line antibiotics, Rib-X says delafloxacin is a broad
spectrum antibiotic that has the potential to treat Gram-negative and
Gram-positive bacterial infections, including for
methicillin-resistant Staphylococcus aureus. 
"In the case of these three companies, they are targeting substantial
markets with innovative therapies," says Burrill. "These financings
may signal that venture investors are growing more confident about
the economy, their ability to raise money, and exit investments on
their own terms when the time is right." 
Overall, life sciences companies raised more than $1.2 billion in
venture financings in November, up from $940 million for the same
period a year ago. In the United States, life sciences venture
financings grew to $928 million in November, up from $700 million a
year ago. Through the first 11 months of 2012, both global and U.S.
life sciences venture funding are up nearly 23 percent. 
In public markets, life sciences stocks rebounded in November after a
down month in October. The Burrill Select Index rose 6.6 percent in
November, beating the major market indices. For the month, the Dow
Jones Industrial Average lost .7 percent, the S&P 500 gained .1
percent and the Nasdaq Composite Index climbed 1 percent. 


 
                                                                            
                                                                            
                                                                            
BURRILL                                                                     
 INDICES                                                                    
                                                         Week   Month  Year 
Index       12/30/2011 10/31/2012 11/23/2012 11/30/2012 Change Change Change
Burrill                                                                     
 Select         432.49     575.48     610.17     613.46   0.5%   6.6%  41.8%
Burrill                                                                     
 Large Cap      529.22     693.83     740.39     740.73   0.0%   6.8%  40.0%
Burrill                                                                     
 Mid-Cap        295.33     308.82     310.30     311.35   0.3%   0.8%   5.4%
Burrill                                                                     
 Small Cap       82.75     102.50      99.23     101.78   2.6%  -0.7%  23.0%
Burrill                                                                     
 Diagnostics    175.42     188.74     189.44     189.79   0.2%   0.6%   8.2%
Burrill                                                                     
 Personalized                                                                   
      
 Medicine       100.62     115.99     117.64     118.40   0.6%   2.1%  17.7%
Burrill                                                                     
 Biogreentech   149.36     159.77     157.71     161.77   2.6%   1.3%   8.3%
Canadian                                                                    
 Biotech         59.17      59.98      60.19      60.20   0.0%   0.4%   1.7%
NASDAQ         2605.15    2977.23    2966.85    3005.66   1.3%   1.0%  15.4%
DJIA          12217.56   13096.46   13009.68   13010.61   0.0%  -0.7%   6.5%
S&P 500        1257.60    1412.16    1409.15    1414.13   0.4%   0.1%  12.4%
Amex                                                                        
 Biotech       1091.42    1397.78    1533.01    1546.52   0.9%  10.6%  41.7%
Amex                                                                        
 Pharmaceut                                                                 
 ical           332.94     369.01     364.91     368.27   0.9%  -0.2%  10.6%

 
Atossa Genetics was the sole life sciences IPO in November. The
diagnostics maker, focused on risk assessment for breast cancer,
raised $4 million at $4 per share, the bottom of its target range. A
total of 16 life sciences companies have completed initial public
offerings in the United States through the end of November, the same
as last year. Overall, U.S. life sciences IPOs completed in 2012 are
up an average of 12 percent from their offering price as of the end
of November. 
On the M&A front, Reckitt Benckiser said it would acquire the
nutraceuticals company Schiff Nutritional International for $1.4
billion in the largest announced deal for the month. Overall, it was
a quiet month for M&A transactions as a total of $6.4 billion in
deals were announced, down from $14.3 billion in November 2011.
Through the end of November $101.1 billion in deals were announced,
down 34.5 percent from the activity a year ago. 
Total global public financings in November rose to $16.1 billion, an
18.3 percent increase from activity a year ago. But a $14.7 billion
debt issue by Abbott Laboratories represented the bulk of the
activity in what was an otherwise slow month for public financings of
life sciences companies.  


 
                                                                            
                                                                            
                                                                            
                                                                            
Life Sciences Scorecard in USD M                                            
                                     YTD 11/30/12   YTD 11/30/12    Change  
Global Venture Capital                      11,240          9,139      23.0%
U.S. VC                                      8,475          6,930      22.3%
                                                                            
IPOs (34 in 2012 v. 44 in 2011)              2,080          3,894     -46.6%
U.S. IPOs (16 in 2012 v. 16 in                                              
 2011)                                       1,093          1,394     -21.6%
                                                                            
Global PIPEs                                 4,978          2,923      70.3%
U.S. PIPEs                                   1,728          1,251      38.1%
                                                                            
Global Follow-ons                            6,565          8,424     -22.1%
U.S. Follow-ons                              5,734          4,618      24.2%
                                                                            
Global Other Equity                          1,858            989      87.9%
U.S. Other Equity                              929            675      37.6%
                                                                            
Global Debt Offerings                       46,616         50,324      -7.4%
U.S. Debt                                   38,024         30,718      23.8%
                                                                            
Global Other Debt                           13,209          9,909      33.3%
U.S. Other Debt                             11,710          4,259     174.9%
                                                                            
Total Global Public Financings              75,306         76,463      -1.5%
Total U.S. Public Financings                59,218         42,915      38.0%
                                                                            
Global Partnering                           34,411         32,662       5.4%
U.S. Partner/Licenser                       18,200         18,984      -4.1%
                                                                            
Global M&A                                 101,124        154,309     -34.5%
M&A, U.S. Target                            72,896         91,861     -20.6%

 
November marked the first approved product for Exelixis. The FDA gave
a green light to Cometriq for the treatment of progressive,
metastatic medullary thyroid cancer. The drug inhibits multiple
tyrosine kinases involved in the spread of cancer, the growth of
tumors and the sustainability of tumors. The approval, which was
widely expected, came after close of trading November 29. Exelixis
shares closed down 6.9 percent the following day to close at $4.88.
The agency also approved Pfizer's Xeljanz for the treatment of adults
with moderate to severe active rheumatoid arthritis who have had an
inadequate response to, or who are intolerant of, methotrexate. As of
the end of November, the FDA approved a total of 31 new drugs and
biologics, one more than it approved for the same period a year ago. 
Sanofi cut the price of its new cancer drug Zaltrap by half,
according to a report in The Cancer Letter. That came in response to
a public controversy over the pricing of Zaltrap that erupted after
physicians at Memorial Sloan-Kettering Cancer Center authored an
op-ed in The New York Times praising their hospital's decision to
exclude it from their formulary because of its price and the belief
that Avastin, a competing drug, offered the same benefit at half the
price. The development is seen as a sign of the growing pressure on
drugmakers to prove the value of their new products to justify
pricing. 
With the re-election of President Barack Obama in November and
Democrats retaining a majority in the Senate, the attention in
Washington is shifting from efforts to repeal the administration's
landmark healthcare reform legislation to matters relating to its
implementation. More immediately, though, the focus is on the fiscal
cliff and the specter of automatic spending cuts that loom over
agencies ranging from the National Institutes of Health to the FDA,
and threatens the health of the life sciences industry. 
"This industry has much at stake in the debate underway right now,"
says Burrill. "It is critical that Congress take action and not
jeopardize the nation's ability to innovate, create jobs, and compete
globally." 
About Burrill & Company 
Founded in 1994, Burrill & Company is a diversified global financial
services firm focused on the life sciences industry. With $1.5
billion in assets under management, the firm's businesses include
venture capital/private equity, merchant banking, and media. By
leveraging the scientific and business networks of its team, Burrill
& Company has established unrivaled access and visibility in the life
sciences industry. This unique combination of resources and
capabilities enables the company to provide life sciences companies
with capital, transactional support, management expertise, insight,
market intelligence, and analysis through its investments,
conferences, and publications. Headquartered in San Francisco, the
company oversees a global network of offices throughout the United
States, Latin America, Europe, and Asia. For more information visit:
www.burrillandco.com.   
Contact:
Daniel Levine
Managing Director
Burrill & Company
dlevine@b-c.com
(415) 591-5449 
 
 
Press spacebar to pause and continue. Press esc to stop.